Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Quinolin-4-Amine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.50 |
| ▸ | HSP90AB1 known ✓ | P08238 | 1/20 | 0.50 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.47 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.47 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.47 |
| ▸ | GLA known ✓ | P06280 | 2/20 | 0.45 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.45 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.43 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.43 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.43 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.43 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.43 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.43 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.43 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.43 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 3/20 | 0.95 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinolin-4-Amine SCHEMBL3997934 | 1.00 | NCF1 (0.95) | NCF1LOXL2NR4A2SOS2MAPT | |
| Quinolin-4-Amine SCHEMBL30414452 | 1.00 | NCF1 (0.95) | NCF1LOXL2NR4A2SOS2MAPT | |
| Quinolin-4-Amine SCHEMBL6221275 | 1.00 | NCF1 (0.95) | NCF1LOXL2NR4A2SOS2MAPT | |
| Quinolin-4-Amine SCHEMBL29429801 | 1.00 | NCF1 (0.95) | NCF1LOXL2NR4A2SOS2MAPT | |
| Quinolin-4-Amine SCHEMBL28157630 | 0.98 | NCF1 (0.91) | NCF1LOXL2NR4A2SOS2MAPT | |
| Quinolin-4-Amine SCHEMBL29493365 | 0.98 | NCF1 (1.00) | NCF1LOXL2NR4A2SOS2MAPT | |
| Quinolin-4-Amine SCHEMBL278276 | 0.98 | NCF1 (1.00) | NCF1LOXL2NR4A2SOS2MAPT | |
| Quinolin-4-Amine SCHEMBL5792741 | 0.95 | NCF1 (0.95) | NCF1LOXL2NR4A2SOS2MAPT | |
| Quinolin-4-Amine SCHEMBL14672386 | 0.95 | NCF1 (0.95) | NCF1LOXL2NR4A2SOS2MAPT | |
| Quinolin-4-Amine SCHEMBL20986747 | 0.95 | NCF1 (0.95) | NCF1LOXL2NR4A2SOS2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110325534-B | Substituted imidazoquinolines as NLRP3 modulators | 先天肿瘤免疫公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-111132969-B | Substituted imidazoquinolines as TLR7 agonists | 生物技术公司 | 2024-01-30 | — | — | CN | disclosed |
| EP-4063358-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
| CN-114867719-A | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2022-08-05 | — | — | CN | disclosed |
| EP-4017492-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | Biohaven Therapeutics Ltd. (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-111132969-A | Substituted imidazoquinolines as TLR7 agonists | 生物技术公司 | 2020-05-08 | — | — | CN | disclosed |
| CN-111094287-A | Substituted imidazoquinolines | 生物技术公司 | 2020-05-01 | — | — | CN | disclosed |
| CN-110325534-A | Substituted imidazoquinolines as NLRP3 modulators | 先天肿瘤免疫公司 | 2019-10-11 | — | — | CN | disclosed |
| CN-106432226-B | The prodrug of 1H- imidazo [4,5-c] quinolin-4-amines class and its related compound | 于崇曦 | 2019-08-30 | — | — | CN | disclosed |
| EP-2115140-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF 1H-IMIDAZO [4, 5-C] QUINOLIN-4-AMINES AND RELATED COMPOUNDS WITH VERY HIGH SKIN PENETRATION RATES | Yu, Chongxi (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008093173-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF 1H-IMIDAZO[4, 5-C]QUINOLIN-4-AMINES AND RELATED COMPOUNDS WITH VERY HIGH SKIN PENETRATION RATES | YU CHONGXI (US) | 2008-08-07 | — | — | WO | disclosed |
| EP-1765348-A2 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M Innovative Properties Company (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006028545-A2 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20030139442-A1 | Vasoactive agents | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-24 | — | — | US | disclosed |
| EP-1296991-A1 | SILOXY SUBSTITUTED COCATALYST ACTIVATORS FOR OLEFIN POLYMERIZATION | ExxonMobil Chemical Patents Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1297027-A1 | SILOXY SUBSTITUTED COCATALYST ACTIVATORS FOR OLEFIN POLYMERIZATION | Exxonmobil Chemical Patents Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1262195-A1 | VASOACTIVE AGENTS | Takeda Chemical Industries, Ltd. (JP) | 2002-12-04 | — | — | EP | disclosed |
| WO-2002000738-A1 | SILOXY SUBSTITUTED COCATALYST ACTIVATORS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| WO-2002000666-A1 | SILOXY SUBSTITUTED COCATALYST ACTIVATORS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139442-A1 | Vasoactive agents | VIPR2, VIPR1, GPR4 | HSP90AA1 1191/4885HSP90AB1 1352/4885ADRA1A 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.